ALMS ALUMIS INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$19.06

Period return

+7.90 (+70.79%)

Volume

1.4M

2026-06-05O $20.26 H $21 L $19.03 C $19.06MA5 $19.98MA20 $21.93MA60 $23.48MA120 $22.78

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 19.LowBUY18 days ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2026. 05. 15.LowBUY22 days ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 05. 15.LowBUY22 days ago
Guggenheim: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $40.1 · 10 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
HQ: South San Francisco, CA, United States
Fiscal year end: —
Employees: 225
IPO date: —

View details →

2026. 05. 15.MediumHOLD22 days ago

HC Wainwright & Co.: Neutral